User profiles for Richard E. Rupp
Richard Earl RuppUniversity of Texas Medical Branch Verified email at utmb.edu Cited by 4443 |
Homologous and heterologous Covid-19 booster vaccinations
Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …
have received emergency use authorization in the United States are highly effective, …
[PDF][PDF] Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to …
exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to …
Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2. 4xM2e) in healthy adults
CB Turley, RE Rupp, C Johnson, DN Taylor, J Wolfson… - Vaccine, 2011 - Elsevier
BACKGROUND: The ectodomain of matrix protein 2 (M2e) is a promising candidate for a
broadly protective influenza A vaccine because it is highly conserved and antibodies to M2e …
broadly protective influenza A vaccine because it is highly conserved and antibodies to M2e …
[HTML][HTML] Heterologous SARS-CoV-2 booster vaccinations–preliminary report
Background: While Coronavirus disease 2019 (Covid-19) vaccines are highly effective,
breakthrough infections are occurring. Booster vaccinations have recently received emergency …
breakthrough infections are occurring. Booster vaccinations have recently received emergency …
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
…, S Edupuganti, MJ Mulligan, LA Jackson, RE Rupp… - npj Vaccines, 2023 - nature.com
As part of a multicenter study evaluating homologous and heterologous COVID-19 booster
vaccines, we assessed the magnitude, breadth, and short-term durability of binding and …
vaccines, we assessed the magnitude, breadth, and short-term durability of binding and …
Maternal and infant outcomes among women vaccinated against pertussis during pregnancy
…, JM Hirth, M Rahman, TH Laz, RE Rupp… - Human vaccines & …, 2016 - Taylor & Francis
Tetanus, diphtheria, and acellular pertussis (Tdap) vaccination is recommended for all women
during each pregnancy to prevent pertussis in young infants. However, data on the safety …
during each pregnancy to prevent pertussis in young infants. However, data on the safety …
A brief educational intervention increases providers' human papillomavirus vaccine knowledge
…, M Rahman, JM Hirth, RE Rupp… - Human vaccines & …, 2015 - Taylor & Francis
Recommendation by a healthcare provider is critical to increase human papillomavirus (HPV)
vaccine uptake in the US. However, current deficits in providers' knowledge of HPV and its …
vaccine uptake in the US. However, current deficits in providers' knowledge of HPV and its …
A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine …
KL Russell, RE Rupp, JO Morales-Ramirez… - Human vaccines & …, 2022 - Taylor & Francis
Dengue (DENV) is a mosquito-borne virus with four serotypes causing substantial morbidity
in tropical and subtropical areas worldwide. V181 is an investigational, live, attenuated, …
in tropical and subtropical areas worldwide. V181 is an investigational, live, attenuated, …
A replication-defective human cytomegalovirus vaccine elicits humoral immune responses analogous to those with natural infection
Human cytomegalovirus (HCMV) can cause congenital infections, which are a leading
cause of childhood disabilities. Since the rate of maternal-fetal transmission is much lower in …
cause of childhood disabilities. Since the rate of maternal-fetal transmission is much lower in …
A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial
A conditionally replication-defective human cytomegalovirus (HCMV) vaccine, V160, was
shown to be safe and immunogenic in a two-part, double-blind, randomized, placebo-…
shown to be safe and immunogenic in a two-part, double-blind, randomized, placebo-…